Deal Watch: Roche To Partner With Dualitis On Novel Bispecifics For I&I Indications
Plus deals involving Lisata/Marea, Maruishi/Kringle, Eli Lilly/QurCan, Elvinix/Zealand, Novo/Ascendis, Ratio/RayzeBio, Sernova/Seraxis, Teva/Andarta and more.
Scrip - September 18, 2026

Long Wait Is Good Omen For AstraZeneca’s AVANZAR Lung Cancer Trial
CEO Pascal Soriot’s share purchase suggests that AstraZeneca still doesn’t have the Phase III AVANZAR results for Datroway – which could be good news for the blockbuster bet.
Scrip - September 18, 2026

Ultragenyx Turns To Launch Execution After Long Road For Sanfilippo Gene Therapy
With Fayuvi now approved, Ultragenyx turns to building treatment-center capacity, securing payer access and identifying patients as it prepares to launch its Sanfilippo gene therapy.
Scrip - September 18, 2026

MethodSense Pitches A ‘Consultant In The Box’ To Speed Device Compliance
MethodSense has launched LuminLogic NextGen, an AI-enabled quality and regulatory platform for device and digital-health firms. CEO Rita King says it can stand up a compliance-ready QMS in a day — a "consultant in the box" pitched against the AI-fabricated filings she says now cross her desk.
Medtech Insight - September 18, 2026

Novartis M&A Strategy Not So Bad As Claimed?
The Avidity and MorphoSys acquisitions have come in for criticism of late but in the wider scheme of things, they look like pretty decent business by the Swiss major.
Scrip - September 18, 2026

Biocon’s Pertuzumab Breaks New Ground As EMA Puts Leaner Biosimilar Pathway Into Practice
Biocon Biologics’ Pebrilzo has become the first biosimilar recommended under the EMA’s tailored clinical approach, offering an early test of how far Europe is prepared to reduce clinical development requirements.
Generics Bulletin - September 18, 2026

Medicines UK Chair Outlines Remedies For ‘Fragile’ Off-Patent Sector
Medicines UK, the trade body for off-patent generic and biosimilar medicines, appointed Paul Burden, the UK's country head for Accord Healthcare, as its new chair earlier this year. He spoke to Generics Bulletin about the organization’s plans for the year ahead.
Generics Bulletin - September 18, 2026

AI-Derived Advertising Claims Land Starkey In Hot Water With Watchdog
The NAD has asked Starkey Laboratories to modify or discontinue ad claims for its Omega AI hearing aid, including claims that were based on AI testing.
Medtech Insight - September 18, 2026

Shilpa Gains Local Advantage In MENA Through Biosimilars Deal With Spimaco
Shilpa Biologicals has allied with Saudi firm Spimaco on a portfolio of PD-1 inhibitor biosimilars across the MENA region, with a phased technology transfer planned to establish local manufacturing in Saudi Arabia.
Generics Bulletin - September 18, 2026

TG Sees Ocrevus Biosimilars Boosting Briumvi
TG Therapeutics says Ocrevus biosimilars could boost Briumvi rather than erode its position, while arguing that deep discounts may be needed to sway payers and that its own 2042 patents could hinder future biosimilar competition.
Generics Bulletin - September 18, 2026

Sandoz Adds First Hemophilia Biosimilar In Bio100 Expansion
Sandoz has added a proposed Hemlibra biosimilar through a deal with mAbxience, extending its pipeline into hemophilia as it accelerates toward its Bio100 ambition of more than 100 biosimilars by 2040.
Generics Bulletin - September 18, 2026

Executives On The Move: Prilenia Names A New CMO As Pridopidine Navigates Two Pivotal Trials
Among other moves is PMV Pharmaceuticals hiring a new CCO to lead the launch preparations for rezatapopt with an accelerated approval plan in place.
Scrip - September 18, 2026

People On The Move: Appointments At Stada, Reckitt, Merz Lifecare
A round-up of the latest moves in the consumer health sector: Stada names chief culture and people officer; Reckitt appoints general manager for Latin America; Merz Lifecare makes hire to lead international expansion.
HBW Insight - September 18, 2026

The Center of Gravity Moves Downstream: AI’s Next Act in Clinical Development
An investor and a clinician take stock of where AI is creating durable value in pharma, and where the gap between promise and proof remains wide.
In Vivo - September 18, 2026